Utility of Contrast-Enhanced Transabdominal Ultrasonography to Diagnose Early Chronic Pancreatitis

Table 1

Clinical characteristics of participants.

	Control; ()	Early chronic pancreatitis; ()	Chronic pancreatitis; ()
Age	61.5 (28–74)	66 (54–69)	58.5 (40–67)	0.0913
Sex (M : F)	5 : 1	5 : 2	8 : 0	0.2826
BMI (kg/m^2)	21.4 (18.5–24.5)	21.2 (19.7–29.6)	20.8 (16.2–26.1)	0.9036
Body surface area (m^2)	1.56 (1.47–1.92); ()	1.64 (1.44–1.70); ()	1.62 (1.51–1.79); ()	0.6105
PV/BSA (cm^2/m^2)	38.83 (36.67–42.56); ()	27.26 (18.94–46.38); ()	19.23 (7.48–38.42); ()	0.0879
Amylase (U/L)	100 (38–170)	105 (58–544)	66 (33–127)	0.1675
Lipase (U/L)	33 (27–52); ()	48 (32–132); ()	21 (10–121); ()	0.0564
LDL-cholesterol (mg/dL)	125 (56–155)	92 (60–99)	65 (40–127)	0.0901
Triglyceride (mg/dL)	74 (41–206)	122 (54–399)	72 (39–177)	0.2596
Serum CPR (ng/mL)	1.28 (0.47–2.53)	2.02 (0.17–2.74)	1.55 (0.23–3.17)	0.4047
HbA1c (%: NGSP)	5.7 (5.3–6.0); ()	5.9 (4.7–6.5); ()	8.5 (5.4–9.4); ()	0.0581
PFD test (%)	72.9 (69.6–75.4); ()	71.6 (60.2–78.0); ()	56.3 (18.7–72.7); ()	0.0474

Kruskal-Wallis test, ² test.
BMI: body mass index, BSA: body surface area, and PV: pancreatic volume.
CPR: C-peptide immunoreactivity and PFD: pancreatic function diagnostant.